This study looks at how well a new medicine called amivantamab works when added to regular cancer treatments for head and neck cancer. Head and neck cancer, or HNSCC, affects areas like the mouth and throat. People in the study have cancer that has come back or spread (recurrent/metastatic). They haven't had treatment for this cancer yet. They will get either the new medicine with regular treatments, or just the regular treatments. The regular treatments include drugs like pembrolizumab and carboplatin.

• This study is for adults 18 years or older.
• Participants must not have received any previous treatment for recurrent/metastatic head and neck cancer.
• If you have certain health issues, like untreated brain cancer or heart problems, you cannot join.